https://www.live-feeds.com/feed/earnings-live-updates-eli-lilly-stock-pops-as-strong-glp-1-drug-demand-lifts-results-servicenow-stock-plungesContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/earnings-live-updates-eli-lilly-stock-pops-as-strong-glp-1-drug-demand-lifts-results-servicenow-stock-plungeshttps://www.live-feeds.com/feed/earnings-live-updates-eli-lilly-stock-pops-as-strong-glp-1-drug-demand-lifts-results-servicenow-stock-plunges#u173705Wed, 04 Nov 2026 10:00:42 +0000Eli Lilly shares climbed following a strong earnings report driven by high demand for its blockbuster GLP-1 weight-loss medications, Zepbound and Mounjaro. The pharmaceutical company raised its full-year sales outlook as revenue surged 39 percent, fueled by obesity drug sales and international growth. Concurrently, ServiceNow stock experienced a sharp drop during the broader earnings updates. Eli Lilly also benefited from the Medicare Bridge boon while navigating deal charges that impacted its profit view, highlighting the strong financial momentum of the ongoing obesity-drug boom.Why it matte